Products for Research Use Only

Omapatrilat

CAT: 0804-HY-18208-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-18208-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Omapatrilat is a dual inhibitor of the metalloproteases ACE and NEP with Ki values of 0.64 and 0.45 nM, respectively.
CAS Number
167305-00-2
Product Name Alternative
BMS-186716
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Angiotensin-converting Enzyme (ACE)
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/Omapatrilat.html
Purity
98.87
Solubility
DMSO : ≥ 31 mg/mL
Smiles
O=C([C@@H]1CCC[C@](N21)([H])SCC[C@H](NC([C@@H](S)CC3=CC=CC=C3)=O)C2=O)O
Molecular Formula
C19H24N2O4S2
Molecular Weight
408.53
Precautions
H302, H315, H319, H335
References & Citations
[1]Fryer RM, et al. Effect of bradykinin metabolism inhibitors on evoked hypotension in rats: rank efficacy ofenzymes associated with bradykinin-mediated angioedema.Br J Pharmacol. 2008 Mar;153 (5) :947-55.|[2]Robl JA, et al. Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics asinhibitors of angiotensin-converting enzyme and neutral endopeptidase. J Med Chem. 1997 May 23;40 (11) :1570-7.|[3]Ichiki T, et al. Endothelial permeability in vitro and in vivo: protective actions of ANP and omapatrilat in experimental atherosclerosis. Peptides. 2013 Oct;48:21-6.|[4]Burrell LM, et al. Antihypertensive and antihypertrophic effects of omapatrilat in SHR. Am J Hypertens. 2000 Oct;13 (10) :1110-6.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, protect from light, stored under nitrogen)
Scientific Category
Reference compound1
Clinical Information
No Development Reported